Data as of Aug 22
| +0.01 / +0.79%|
The 4 analysts offering 12-month price forecasts for Navidea Biopharmaceuticals Inc have a median target of 6.00, with a high estimate of 10.00 and a low estimate of 2.00. The median estimate represents a +372.44% increase from the last price of 1.27.
The current consensus among 4 polled investment analysts is to Buy stock in Navidea Biopharmaceuticals Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.